Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Fri Dec 01 00:00:00 GMT-04:00 2017
Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as ...
PDF (194 KB)
Thu Dec 07 00:00:00 GMT-04:00 2017
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at ...
PDF (190 KB)
Mon Dec 11 00:00:00 GMT-04:00 2017
Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin ...
PDF (252 KB)
Tue Dec 12 00:00:00 GMT-04:00 2017
​​​​​​​Once-Daily, Oral SAVAYSA® (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CAN ...
PDF (230 KB)
Tue Dec 12 00:00:00 GMT-04:00 2017
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in H ...
PDF (215 KB)
Thu Jan 18 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ...
PDF (271 KB)
Tue Feb 06 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Smal ...
PDF (180 KB)
Thu Feb 22 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Can ...
PDF (181 KB)
Wed Feb 28 00:00:00 GMT-04:00 2018
Daiichi Sankyo, Inc. Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pip ...
PDF (148 KB)
Wed Mar 07 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorec ...
PDF (213 KB)
Showing 1 - 10 of 43 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...